Overview of currently approved drugs for the treatment of HBV infections*

Interferon α
Standard Interferon α-2aRoferon®2.5–5 mio. U/m2
body surface 3x/week
4–6 months
Standard Interferon α-2bIntron A®5–10 mio. IU 3x/week4–6 months
Pegylated Interferon α-2aPegasys®180 µg/week48 weeks
Nucleoside analogues
Lamivudine (LAM)Epivir®, Zeffix®100 mg/daylong-term
Telbivudine (LdT)Tyzeka®,Sebivo®600 mg/daylong-term
Entecavir (ETV)Baraclude®0.5 mg/day, 1 mg/day for patients with
lamivudine resistance
Nucleotide analogues
Adefovir dipivoxil (ADV)Hepsera®10 mg/daylong-term
Tenofovir disoproxil fumarate (TDF)Viread®300 mg/daylong-term
Tenofovir alafenamide (TAF)Vemlidy®25 mg/daylong-term
generic drugs are not listed
Author Profile

Dr. D.Zeqiraj medical doctor at QKUK- Pristina, department of Infectious disease.